Investors Are Betting Big Against Insys Therapeutics — Here’s Why You Shouldn’t

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 26 July, 2016 by The TZ Newswire Staff

Investors Are Betting Big Against Insys Therapeutics — Here’s Why You Shouldn’t

I made a huge mistake.

Image source: Getty Images.

Pessimism surrounding Insys Therapeutics (NASDAQ: INSY) is off the charts. It is far and away the most heavily shorted stock on its exchange, with about 73% of shares outstanding betting against its success.

See also
- Next Article Why Sanmina Corp. Stock Plunged Today
- Previous Article Here’s What to Look For in Suncor Energy’s Q2 Earnings
Editorial Calender

July 2016

M T W T F S S

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30 31

« Jun Aug »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 26 July, 2016 by The TZ Newswire Staff

Investors Are Betting Big Against Insys Therapeutics — Here’s Why You Shouldn’t

See also

Editorial Calender

Recent Tags